COVID-19 Funding Opportunities

COVID-19 Research Grants for Combating the coronavirus crisis

Various government agencies, companies, and foundations have announced non-dilutive funding opportunities to encourage research and development to address the novel Coronavirus pandemic. Some of these opportunities allow applicants to propose new projects addressing COVID-19, while others provide funding to expand the scope of existing awards to include COVID-19-related research.

As the COVID-19 situation continues to develop, EGC will maintain an updated list of relevant funding opportunities here. Click below to be notified as new COVID-19 research grants are announced.

Expand/Collapse All
Biomedical Advanced Research and Development Authority (BARDA)

BARDA continues to solicit proposals for the development of diagnostic assays and therapeutics for COVID-19 and encourages applicants to participate in a TechWatch meeting prior to submitting a white paper or full proposal in response to its current Broad Agency Announcement

BARDA BAA

View Solicitation

Topic: Proposals for diagnostic assay development are solicited under Area of Interest (AOI) 7.7; projects to develop COVID-19 therapeutics, including direct-acting antivirals and host-directed therapeutics, may be submitted under AOI 9.2; and projects to develop and demonstrate innovations and enhancements to pharmaceutical manufacturing platforms to support the development of vaccines and therapeutics for COVID-19 can be submitted under AOI 17


CoronaWatch

Request CoronaWatch Meeting

While CoronaWatch is not a direct funding mechanism, the U.S. government seeks information from stakeholders on available medical countermeasures in development for COVID-19. A CoronaWatch meeting is held by interactive webinar, in which the presenting team displays slides and engages with government personnel.  A CoronaWatch meeting is encouraged prior to applying for BARDA funding, so that organizations can better align their product development with government priorities.


National Institutes of Health (NIH) DEADLINE APPROACHING

NIA Multi-site COVID-19 Related Clinical Trial
NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)

Description: The National Institute on Aging (NIA) invites applications for the implementation of investigator-initiated multi-site clinical trials (at all phases or stages) of interventions focused on specific aging-related issues and aimed at reducing the transmission, risk, morbidity, mortality, severity, or complications of COVID-19.

Topics:

  • Efficacy and safety of interventions that target aging-related biological mechanisms that may influence risk or severity of COVID-19 infection among at-risk older adults
  • Efficacy and safety of preventive and treatment interventions in older patients with differing comorbid conditions that make them especially vulnerable to adverse outcomes of COVID-19 infection
  • Effectiveness of health and/or custodial care practices to reduce transmission risk or improve outcomes of COVID-19 infection in nursing homes or other residential settings serving at-risk older persons, including the development and testing of infection control training procedures for healthcare workers
  • Rapid pragmatic trials in (at least two) health systems, nursing homes, or adult living facilities, ensuring replication across large pragmatic trial sites and leveraging electronic health records to promote quality improvement in physician, hospital, palliative care, and hospice practices to improve outcomes for older patients with COVID-19, especially those with cognitive impairment, Alzheimer’s disease or Alzheimer’s disease-related dementias (AD/ADRD), or underlying comorbidities
  • Trials in at-risk older adults aged 65 and older for whom electronic medical records are available and long-term outcomes can be tracked and in institutions serving those populations
  • Trials in older adults with AD/ADRD, older adults from populations with NIH-defined health disparities, and/or other vulnerable populations (e.g., incarcerated, homeless, living in institutions)

Due Dates: 2/1/2021
Budget: Not Limited


Notices of Special Interest (NOSI)

Multiple NIH Institutes have issued Notices of Special Interest (NOSIs) to provide funding for research topics related to COVID-19.  For most of these opportunities, the applicant must have an active award through the Institute with sufficient time remaining to complete all studies proposed.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract

Description: The NICHD invites applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. This NOSI is interested in the recently emergent ZIKA and novel corona viruses, as well as other yet unidentified viruses which may significantly impact public health. Proposals should be submitted to either PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) or PA-18-482 NICHD Exploratory/Developmental Research Grant (R21 – Clinical Trial Optional).

Topics: Areas of interest of this NOSI include, but are not limited to:

  • Consequences of infection, e.g., cells affected and outcomes of infection – infertility, miscarriage, live births, orchitis, epididymitis, pelvic pain;
  • Mechanism of action for infectivity of reproductive tract tissues;
  • Whether the reproductive tract acts as a reservoir for viruses;
  • Sex-specific differences in infection as they may relate to reproductive tract tissues and cells;
  • The impact of race and ethnicity on reproductive system impacts of viruses;
  • Impact of nutrition, e.g., Vitamin D sufficiency and the understanding of mechanisms that explain the impact of obesity;
  • Development of model systems to study infections in reproductive tract tissues, e.g., organoids (for R21 applications only)

Due Dates: Standard R01 due dates apply. This NOSI expires on 5/8/2023 .
Budget: Not limited


Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities
View solicitation

Description: The NIH has released a Notice of Special Interest to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities, including those related to COVID-19. Proposals should be submitted using the funding opportunity announcement “PA-20-185 – NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).”

Topics: The specific areas of interest of each participating institute or center are listed in the NOSI (see link), but in general, proposals are solicited for projects addressing the following research objectives:

  • Foster trans-disciplinary partnerships and collaborations in understanding the etiology and causal pathways of health disparities using simulation modeling and systems science (SMSS)
  • Use SMSS to identify modifiable barriers and cost-effective factors to reduce and eventually eliminate health disparities
  • Use SMSS to improve patient safety and reduce medical errors for populations affected by health disparities
  • Use SMSS to assess and predict the spread and consequences of pandemics (e.g., SARS-CoV-2) and the effectiveness of interventions in populations affected by health disparities
  • Provide evidence-based simulation or prediction of the impact of effective or ineffective health disparities interventions delivered in real-world settings
  • Promote big data harmonization and novel analytic methods in SMSS to address minority health and health disparities

Due Dates: Standard R01 due dates apply. This NOSI expires on 5/8/2023 .
Budget: Not limited


NIA/NIMH
NOSI: Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
  • PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements for NIH grantees applying to expand the scope of their active grant.
  • PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

Topics:  NIA – Mission critical areas as they relate to the COVID-19 pandemic. NIMH – Applications addressing care for new or worsening mental health needs and/or suicide risk in midlife and older age adults will be seen as a high priority.

Due Date: Rolling until 5/1/2021
Budget: Limited to no more than that amount of the current parent award.


National Institute of Allergy and Infectious Diseases (NIAID) Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)

View solicitation

Description: This program will support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age). Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.

Topics: Examples of research areas of interest include, but are not limited to :

  • Mechanisms regulating the generation and maintenance of T and B cell memory;
  • Molecular mechanisms of innate immunity, including trained immunity;
  • Effect of the microbiota on host immune development and response;
  • Mechanisms of tissue-specific and mucosal immunity;
  • Role and mechanisms of action of adjuvants/immune-potentiating molecules or compounds for improving protective immune responses in children; 
  • Impact of sex differences on innate and adaptive immune development and function;
  • Impact of maternal factors on immune system development in early life that include examination of longer-term effects in the child;
  • Mechanism by which environmental exposures affect the functionality of the pediatric immune system;
  • Mechanisms regulating exhaustion of the immune response to chronic infection or exposure, and impact on vaccine responses;
  • Metabolic and/or epigenetic regulation of the pediatric immune response;
  • HIV:

    -Key factors impacting the pediatric immune response and efficacy of HIV vaccine candidates and other HIV-prevention strategies;
    -Broadly neutralizing antibody development during pediatric immune maturation;
    -Longitudinal imaging of immune cell dynamics and immune responses to vaccines or other prevention strategies in the pediatric population;
    -Development of mucosal immunity in the context of vaccine/prevention strategies;
    -Studies testing or proposing development of drugs/vaccines to prevent infection that is specific to the pediatric population.

Due Dates: 6/4/2021
Budget: $1 million direct costs per year


Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)

View solicitation

Description: This program will support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age). Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.

Topics: This program will support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age). Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.

  • Mechanisms regulating the generation and maintenance of T and B cell memory;
  • Molecular mechanisms of innate immunity, including trained immunity; Effect of the microbiota on host immune development and response; Mechanisms of tissue-specific and mucosal immunity;
  • Role and mechanisms of action of adjuvants/immune-potentiating molecules or compounds for improving protective immune responses in children; 
  • Impact of sex differences on innate and adaptive immune development and function; Impact of maternal factors on immune system development in early life that include examination of longer-term effects in the child;
  • Mechanism by which environmental exposures affect the functionality of the pediatric immune system;
  • Mechanisms regulating exhaustion of the immune response to chronic infection or exposure, and impact on vaccine responses;
  • Metabolic and/or epigenetic regulation of the pediatric immune response;
  • HIV:

    -Key factors impacting the pediatric immune response and efficacy of HIV vaccine candidates and other HIV-prevention strategies;
    -Broadly neutralizing antibody development during pediatric immune maturation;
    -Longitudinal imaging of immune cell dynamics and immune responses to vaccines or other prevention strategies in the pediatric population;
    -Development of mucosal immunity in the context of vaccine/prevention strategies;
    -Studies testing or proposing development of drugs/vaccines to prevent infection that is specific to the pediatric population.

Due Dates: 6/4/2021
Budget: $500,000 direct costs per year


Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects

View solicitation

Description: NIAID has issued a Notice of Special Interest (NOSI) to highlight the critical need to develop prophylactic vaccines that are able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. NIAID is particularly interested in highly collaborative, multi-disciplinary Program Projects (P01s) that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains.

Topics: Particular areas of interest include:

  • Identification of broadly reactive B- and T-cell epitopes;
  • Structural studies of CoV proteins related to designing novel, effective immunogens;
  • Rational design of CoV immunogens to elicit broadly neutralizing, durable antibodies against multiple CoVs;
  • Studies to understand the role of antigen-specific T cell responses in immunity to CoVs, including strategies to induce T-cell immunity;
  • Studies to identify correlates of protection against CoVs following natural infection or vaccination;
  • Studies to understand vaccine-induced responses across the life span, including investigation of age- or sex-related effects on vaccine efficacy;
  • Studies to understand the impact of previous exposure to CoVs on subsequent vaccine responses;
  • Studies to identify antigen/adjuvant combinations to induce potent and broad protection against multiple CoVs;
  • Development of multi-valent and next-generation vaccine platforms/strategies to provide durable immunity to multiple CoVs, and that are suitable for use in vulnerable populations;
  • Iterative studies and head-to-head comparisons of candidate vaccines in relevant preclinical models are encouraged to advance the most promising vaccine candidates;
  • Strategies to direct protective immune responses to relevant tissues, such as mucosal sites.

Due Dates: 6/11/2021
Budget: Not limited


Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

View solicitation

Description: The National Institute of Allergy and Infectious Diseases has issued a Notice of Special Interest encouraging cooperative agreement applications for the implementation of investigator-initiated, high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2. Proposals should be submitted using the funding opportunity announcement “PAR-18-633 NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required).”

Topics: Proposals are sought to evaluate SARS-CoV-2 candidate vaccines, non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19, and therapeutic approaches to treat COVID-19. Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative

Due Dates: Applications will be accepted once a month from 09/14/2020 through 09/14/2021
Budget: Not limited


NOSI: Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Topics: Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

Due Date: Rolling until 3/25/2021
Budget: Not Specified


Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)

Description: The National Institute of Allergy and Infectious Diseases (NIAID) has released a new funding opportunity to provide personal protective equipment to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 and the Coronavirus Aid, Relief and Economic Security (CARES) Act.

Topics: Purchase of personal protective equipment for use in COVID-19 clinical trials or clinical studies

Due Date:  Applications are accepted on a rolling basis
Budget: Not limited


National Institute of Arthritis and Musculoskeletal and Skin Diseases(NIAMS)
Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases

Description: NIAMS would like to promote basic, translational, pre-clinical and clinical observational research focused on COVID-19 infection and its intersection with rheumatic, musculoskeletal, and skin diseases and conditions. While there is no obvious indication of adverse events or impacts of the use of COVID-19 vaccines in individuals with underlying rheumatic, skin, and or musculoskeletal diseases/conditions, research studies should be carried out to determine if these individuals will be affected differently by COVID-19 vaccines and treatments as compared to those without such conditions.

Topics: This NOSI encourages, but is not limited to, research applications focused on:

  • Susceptibility to, prevalence, risk assessment, and clinical management of COVID-19 among patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
  • The impacts of drugs or other targeted therapies that are used to treat diseases within the mission of NIAMS on susceptibility, severity, and management of COVID-19;
  • Health disparities and social/behavioral factors that contribute to risk of infection, organ injury and adverse outcomes in COVID-19 patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
  • Impact of COVID-19 vaccination of patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
  • Characterization of long-term post-acute sequelae occurring in recovered COVID-19 patients with co-existing rheumatic, musculoskeletal, and/or skin diseases;
  • Characterization of NIAMS-mission related long-term post-acute sequelae (e.g. muscle pain, joint pain, biobehavioral changes, skin rash, arthritis, etc.) occurring in recovered COVID-19 patients.

Due Date: February 5 through November 18, 2021
Budget: Not Specified


National Institute of General Medical Sciences (NIGMS)
NOSI: Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Topics: Predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only).

Due Date: Rolling, through 2/6/2021
Budget: Not Specified


National Center for Advancing Translational Sciences (NCATS) DEADLINE APPROACHING

Notice of Special Interest (NOSI): Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

Description: The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) UL1 component award recipients from these FOAs:

  • PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional)

Topics: Provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data

Due Dates: Applications will be accepted on a rolling basis until 5 PM local time on 6/1/2021
Budget: $30,000 to $60,000 in direct costs


Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19

Description: NCATS is soliciting applications to PAR-17-465 (Bench Testing Therapeutic/Indication Pairing Strategies [UG3/UH3]), PAR-18-462 (Clinical Trial Planning: Therapeutic/Indication Pairing Strategies [U34] [Clinical Trial Not Allowed]), and PAR-18-332 (Clinic Testing Therapeutic/Indication Pairing Strategies [U01 Clinical Trial Required]) to repurpose for COVID-19 treatment existing drugs or biologics that have already begun or completed a Phase I clinical trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair, such as testing a publicly posted therapeutic candidate for use to treat COVID-19, testing a candidate therapy to treat COVID-19 that was already identified with a publicly available computational approach, and testing of existing therapeutic candidates that work on mechanistic targets shared among other viruses that may be relevant to SARS-CoV-2.

Topics:

  • Bench testing therapeutic/indication pairing strategies
  • Clinical trial planning for therapeutic/indication pairing strategies
  • Clinic testing of therapeutic/indication pairing strategies

Due Dates: See application due dates in the corresponding solicitations. This NOSI expires on 3/17/2021
Budget: $100,000 in direct costs (UH3), $200,000 in direct costs per year (UG3), $225,000 in direct costs (U34), $3,000,000 in direct costs per year (U01).


Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)
DEADLINE APPROACHING

Description: The National Center for Advancing Translational Sciences has released an urgent U01 funding opportunity announcement to invite applications to repurpose existing therapeutic agents to treat COVID-19 sequelae and associated complications that result from SARS-CoV-2 infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

Topics: Clinical trials of existing therapeutic agents for treating COVID-19

Due Dates: Applications are accepted on a rolling basis until 1/24/2021.
Budget: $3,000,000 in direct costs per year for up to 3 years


NOSI: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need

Topics: Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

PAR-19-099 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)

Due Dates: 3/8/2021, 7/9/2021
Budget: $400,000 – $750,000

PAR-19-100 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)

Due Dates: 3/8/2021, 7/9/2021
Budget: $275,000 (direct costs)


NOSI: Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus DEADLINE APPROACHING

Topic: Use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Due Date: Rolling through 01/26/2022
Budget: 25% total costs of current parent award


National Institute of Drug Abuse (NIDA)
NOSI: Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

Topic: NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Due Date: Rolling, through 3/31/2021
Budget: Maximum of $100,000 direct costs per year for 2 years.  Higher budgets may be considered with justification.


National Institute of Neurological Disorders and Stroke (NINDS)
NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

Description: NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Topics: Biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronovirus

Due Dates: Applications accepted on a rolling basis until 4/14/2021
Budget: $200,000 in direct costs


Depart of Defense (DoD)
Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) Commercial Solutions Opening

View Solicitation

Description: The DAF ACT Commercial Solutions Opening (CSO) is a contract opportunity that seeks innovative, commercial technologies that propose new solutions and/or potentially new capabilities that fulfill requirements, close capability gaps, or provide potential technological advancements in support of the COVID-19 Response Acquisition Task Force mission to provide relief, resilience, recovery, and stability to the nation in response to the COVID-19 pandemic. This CSO may have areas of interest (AoIs) that result in an award of prototype projects, which include not only commercially available technologies fueled by commercial or strategic investment but also concept demonstrations, pilots, and agile development activities that can incrementally improve commercial technologies, existing government-owned capabilities, and/or concepts for broad defense and/or public application(s). Solution Briefs will be solicited by the posting of DAF ACT AoIs within predetermined Mission Focus Areas that identify generalized areas of need. All AoIs will be posted as amendments to the CSO solicitation at https://beta.sam.gov/.

Topics: The seven Mission Focus Areas for this contract opportunity are as follows:

  • Masks/Fiber/Materials
  • Screening & Diagnostics
  • Gloves/Gowns
  • Pharmaceuticals
  • Logistics (security and protection, supply chain protection and assessment, etc.)
  • Medical (telehealth, medical capacity, and sustainment, medical supplies and equipment, etc.)
  • Other – Any solution/proposal that is not covered by the above topic areas but support the national response to the COVID-19 pandemic

Due Date: Various (see individually published AoIs for details)
Budget: Not specified

US Department of Agriculture (USDA)
National Institute of Food and Agriculture (NIFA)

In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines.

Agriculture and Food Research Initiative (AFRI)

View Solicitation

Topics: Focus areas of interest include, but are not limited to the following:

  • Animal Nutrition, Growth and Lactation (A1231)
  • Critical Agricultural Research and Extension (CARE) (A1701)
  • Diseases of Agricultural Animals (A1221)
  • Food Safety and Defense (A1332)
  • Foundational Knowledge of Plant Products (A1103)
  • Economics, Markets, and Trade (A1641)

Due Date: Varies by Program
Budget: $1,000,000


Other US Funding Sources
ImpactAssets and Stop the Spread

ImpactAssets Stop the Spread COVID Response Program

Description: Stop the Spread’s COVID Response Program is keenly focused on working with companies and organizations—large and small—to spur development of PPE for both medical and non-medical use, novel testing solutions, widely-accessible therapeutics and digital health solutions to address the needs of underserved communities and vulnerable populations.

Topics:

  • Testing
  • Vaccines
  • Hyperlocal Support
  • Health Services
  • PPE
  • Therapeutics
  • Ventilators

Due Date: Not Specified
Budget: Not Specified


Wellcome, Bill & Melinda Gates Foundation, and Mastercard

The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.

View Announcement

Topics: The Accelerator is seeking partners for the following activities:

  • Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
  • Developing drugs or monoclonal antibodies that pass initial screening.
  • Scaling up production and commercialization of successful drugs and monoclonal antibodies.

Due Date: Not Specified
Budget: Not Specified; Total Program Budget – $125,000,000


Fast Grants

Fast Grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.

View Solicitation

Topics: All COVID-19 related science

Due Date: Rolling, award decisions made in 48 hours.
Budget: $10,000 – $500,000


International Opportunities DEADLINE APPROACHING
Global DEADLINE APPROACHING Global Innovation Fund

GIF COVID-19 Response

Description: The Global Innovation Fund is a non-profit innovation fund that invests in the development, rigorous testing, and scaling of innovations targeted at improving the lives of the world’s poorest people, i.e., those living on less than $5 a day. For-profit companies located anywhere in the world can apply for funding for projects that address COVID-19 in developing countries. GIF supports innovators at all stages of their life cycle, from start-up and pilot-testing through to larger-scale implementation.

Topics: Innovations to assist with COVID-19 response and related issues affecting people living on less than $5 a day in developing countries.

Due Dates: Applications are accepted on a rolling basis
Budget: $50,000 to $15,000,000 depending upon project stage and needs. Grants are available to for-profit companies where appropriate, but other forms of investment are also used.


Asian Development Bank DEADLINE APPROACHING

COVID-19 Vaccine: Safety and Immunization Monitoring

ADB Digital – COVID-19 Vaccine: Safety and Immunization Monitoring

Description: The Asian Development Bank has launched a series of challenges calling for digital health solutions to help achieve successful vaccination programs in the developing countries that it serves. The first of these is related to the development of digital tools for vaccine safety and immunization monitoring. The Challenge includes Application, Evaluation, Mentoring, and Pitching phases, culminating in selection of the winning solution by a panel of experts.

Topics: Proposed solutions should address the following areas:

  • Providing the general population with accurate and timely information about accredited COVID-19 vaccine administration sites
  • Setting clear expectations about common side effects following vaccination
  • Actively monitoring mild and potentially more serious side effects post-vaccination
  • Sending reminders for the second dose (if needed depending on vaccine type).
  • Clearly addressing potential concerns related to COVID-19 vaccine safety and hesitancy
  • Educating the public about the benefits of COVID-19 vaccination to increase public confidence

Due Dates: 1/31/2020
Budget: Up to $50,000 will be awarded to support pilot projects in ADB’s developing member countries.


Asian Development Bank DEADLINE APPROACHING COVID-19 Vaccine: Safety and Immunization Monitoring ADB Digital – COVID-19 Vaccine: Safety and Immunization Monitoring

Description: The ADB’s second challenge addresses the tracking of administered vaccines in the bank’s developing member countries. The challenge calls for digital health solutions to support large, complex vaccination programs involving two-dose COVID-19 vaccines.

Topics: Proposed solutions should address the following areas:

  • Informing people about what vaccine they are getting and reminding them to get the second vaccination
  • Assisting health care providers with tracking of who has received which vaccine so that they can provide the correct second dose
  • Supporting governments in distributing the right type of vaccine to the right geographic regions within the country to avoid stock-out, especially when people are ready for the second dose

Due Dates: 1/31/2020
Budget: Up to $50,000 will be awarded to support pilot projects in ADB’s developing member countries.


The Trinity Challenge DEADLINE APPROACHING

View Solicitation

Description: The Trinity Challenge is a coalition of globally leading institutions from the private and public sectors (“Founding members” and “Members”) that has formed around the core idea of the present challenge, which aims to support improved responses to future pandemics. The Trinity Challenge will focus on generating, identifying and recognizing insights through data and analytics. Challenge applicants must provide ideas and concepts addressing at least one of three areas in which to improve our approach towards pandemic prevention & control: Better identification, better response, and better recovery. Significant support and awards will be given to the best contributions around pandemic preparedness and response for the inaugural round running from autumn 2020 to spring 2021. Applicants are encouraged to collaborate with Founding Members of The Trinity Challenge, although this is not a requirement.

Topics:Application of data analytics to the following facets of pandemic response:

  • Better identification of zoonotic threats
  • Identification of effective methods of preventing disease transmission and spread with the least societal and economic costs
  • Identification of ways to address the disproportionate health and economic impact of outbreaks and pandemics, particularly on vulnerable groups

Due Dates: 1/30/2021 (for independent applications requiring no Founding Member support)
Budget: Not specified


United Kingdom

UK Research and Innovation (UKRI)

Proposals will be accepted from anyone who is normally eligible to apply for UKRI funding. You will need to show that you can start work within 4 weeks of the funding being confirmed.

View Solicitation

Topics: Short-term projects (12-18 months) addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.

Due Date: Ongoing
Budget: 80% of the full economic cost


Urgent COVID-19 proposals

Description: UKRI has made seed funding available for urgent COVID-19-related projects with a maximum duration of 6 months and a clear path forward once the urgent phase is completed. Urgent applications will be reviewed on a two-week basis with the expectation that the project would start within a month. Non-urgent COVID-19 proposals can be submitted through UKRI’s standard grant routes.

Topics: Urgent projects include those involving the collection of data or samples or rapid turnaround of initial research that is essential to secure future research or inform urgent policy or national/international decisions.

Due Dates: Applications are accepted on a rolling basis.
Budget: £80,000


Get funding for ideas that address COVID-19

Description: Proposals are invited for short-term projects addressing and mitigating the health, social, economic, cultural, and environmental impacts of the COVID-19 outbreak. 

Topics: An extensive list of research questions can be found at https://www.ukri.org/files/research-questions-for-covid-19/. These questions focus on various areas, including:

  • COVID-19 treatments
  • Contact tracing
  • Epidemiology
  • Data availability and use
  • Modeling and prediction
  • Accelerated use of AI and automation
  • National security and geopolitics
  • Engineering
  • Inequalities
  • Behavioral insights

Due Dates: None. Applications are accepted on a rolling basis.
Budget: Not specified